Kedu ihe kpatara eji ewere ntụ ntụ Rivaroxaban n'abalị?

Rivaroxaban bụ ọgwụ anticoagulant edebere iji gbochie na ịgwọ mkpụkọ ọbara na ọnọdụ ahụike dị iche iche, dị ka thrombosis miri emi, pulmonary embolism, na atrial fibrillation. Ọ bụ ezie na a na-aṅụ ọgwụ ahụ otu ugboro ma ọ bụ ugboro abụọ kwa ụbọchị, a na-adụ ndị ọrịa ụfọdụ ọdụ ka ha were ya rivaroxaban ntụ ntụ n'abalị. Edemede a ga-enyocha ihe kpatara nkwado a yana ajụjụ metụtara okwu.

Rivaroxaban so na klaasị ọgwụ a maara dị ka ọgwụ mgbochi mgbochi ọnụ (DOACs) ma ọ bụ ọgwụ mgbochi ọnụ (NOACs). N'adịghị ka anticoagulants ọdịnala dị ka warfarin, rivaroxaban na-egbochi ozugbo Factor Xa, enzyme bụ isi n'ime mkpụkọ ọbara. Usoro a na-eme ihe na-enye mmetụta anticoagulation karịa nke a na-ahụ anya ma na-ebelata mkpa ọ dị maka nlekota ugboro ugboro nke ọkwa mkpọchi ọbara.

Mkpebi ị were rivaroxaban n'abalị dabere n'ọtụtụ ihe, gụnyere ọgwụ ọgwụ pharmacokinetics nke ọgwụ, mmetụta ndị nwere ike ime, yana mkpa onye ọrịa. Site na iji rivaroxaban na mgbede, ndị ọrịa nwere ike irite uru site na nrapagidesi ike na usoro ọgwụ ha na enwere ike belata ohere nke ụfọdụ mmetụta.

Kedu ihe mmetụta dị na ịṅụ rivaroxaban n'abalị?

Rivaroxaban, dị ka ọgwụ mgbochi ndị ọzọ, nwere ike ịkpata mmetụta dị n'akụkụ, ụfọdụ n'ime ha nwere ike ịpụta karịa mgbe a na-ewere ya n'abalị. Mmetụta ndị a na-ahụkarị gụnyere ọbara ọgbụgba, ọnya, ọgbụgbọ, na dizziness. Otú ọ dị, ịṅụ rivaroxaban n'abalị nwere ike ibelata ihe ize ndụ nke mmetụta ụfọdụ, dị ka ọbara ọgbụgba nke eriri afọ, nke nwere ike ime n'ụbọchị mgbe afọ na-agbari nri.

Otu n'ime ihe kacha echegbu ya na rivaroxaban na ọgwụ mgbochi ọbara ndị ọzọ bụ mmụba ọbara ọgbụgba. Ihe ize ndụ a nwere ike ịpụta n'ụzọ dị iche iche, site na obere okwu dị ka ọbara ọgbụgba na-adịte aka site na mbepu ma ọ bụ ọbara imi ruo nsogbu ndị ka njọ dị ka ọbara ọgbụgba n'ime. Inweta rivaroxaban n'abalị nwere ike inye aka kesaa mmetụta anticoagulant karịa n'ime oge awa 24, nwere ike ibelata mkpokọta kachasị elu nke nwere ike ibute nnukwu ọbara ọgbụgba n'oge mmemme kwa ụbọchị.

Ndị ọrịa nwekwara ike ịnweta ike ọgwụgwụ ma ọ bụ iro ụra dị ka mmetụta dị n'akụkụ nke Rivaroxaban Powuru. Site n'ịṅụ ọgwụ n'abalị, mmetụta ndị a nwere ike ghara ịdị na-ahụ anya ma ọ bụ na-enye nsogbu, ebe ọ bụ na ha na-adaba na usoro ụra nke anụ ahụ. Oge a nwere ike inye aka melite nnabata n'ozuzu ya na nrube isi n'usoro ihe edeputara.

Ọ dị mkpa iburu n'obi na rivaroxaban nwere ike iji ọgwụ ndị ọzọ emekọrịta ihe, mgbakwunye, na ụfọdụ nri, nwere ike ịbawanye ohere nke ọbara ọgbụgba ma ọ bụ mmetụta ọjọọ ndị ọzọ. Dịka ọmụmaatụ, iji Rivaroxaban na ndị ọzọ na-ebelata ọbara, ọgwụ ndị na-adịghị steroidal anti-inflammatory (NSAIDs), ma ọ bụ ụfọdụ ọgwụ na-egbu egbu nwere ike ịbawanye ohere nke ọbara ọgbụgba. Na mgbakwunye, iri nnukwu mkpụrụ osisi grepu ma ọ bụ mkpụrụ osisi grepu nwere ike imetụta metabolism nke rivaroxaban, nwere ike ịgbanwe arụmọrụ ya.

Ndị ọrịa kwesịrị iso ndị na-ahụ maka ahụike ha kparịta usoro ọgwụ ha zuru oke na omume nri iji hụ na ejiri Rivaroxaban dị mma ma dị mma. Nke a gụnyere ikpughe ọgwụ ọ bụla a na-ere ahịa, ihe mgbakwunye ahịhịa, ma ọ bụ mgbanwe nri nke nwere ike imetụta arụmọrụ ọgwụ ma ọ bụ profaịlụ nchekwa.

Enwere ike iji rivaroxaban were nri ma ọ bụ na afọ efu?

Rivaroxaban Powuru enwere ike iji ya ma ọ bụ enweghị nri, ebe ọnụnọ ma ọ bụ enweghị nri anaghị emetụta nnabata ya na bioavailability nke ukwuu. Agbanyeghị, ụfọdụ ndị ọrịa nwere ike ịnwe ahụ erughị ala afọ ma ọ bụ ọgbụgbọ mgbe ha na-ewere rivaroxaban na afọ efu, ọkachasị ma ọ bụrụ na ha nwere afọ nwere mmetụta.

Iji nri dị mfe ma ọ bụ obere nri were rivaroxaban n'abalị nwere ike inye aka belata mmetụta ndị nwere ike ime. Ụzọ a nwere ike ịba uru karịsịa maka ndị ọrịa na-enwekarị iwe iwe ma ọ bụ ndị na-enwe ọgbụgbọ na ọgwụ ndị ọzọ n'oge gara aga. Ọnụnọ nke nri dị n'ime afọ nwere ike inye aka chekwaa ọgwụ ahụ ma belata mgbakasị ahụ na eriri afọ.

Ọ dị mkpa ịgbaso ntuziaka akọwapụtara nke onye na-ahụ maka ahụike gị nyere gbasara oge na nchịkwa nke rivaroxaban n'ihe gbasara nri. Ọ bụ ezie na nri anaghị emetụta mmịnye ọgwụ ahụ nke ukwuu, ịnọgide na-enwe otu esi aṅụ ọgwụ ahụ nwere ike inye aka hụ na ọkwa ọbara kwụsiri ike yana mmetụta anticoagulant a na-ahụ anya.

Maka ndị ọrịa na-ewere oke doses nke rivaroxaban (15 mg ma ọ bụ 20 mg) maka ọnọdụ ndị dị ka atrial fibrillation, a na-atụ aro ka ị were nri were ọgwụ ahụ were kwalite nnabata. Ndụmọdụ a dabere na ọmụmụ ọgwụ ọgwụ na-egosi nkwalite bioavailability dị mma mgbe ejiri nri were were ọgwụ.

Kedu ka oge usoro onunu ogwu Rivaroxaban si emetụta arụmọrụ ya?

Oge usoro onunu ogwu rivaroxaban nwere ike imetụta nrụpụta ya na nchekwa ya. Rivaroxaban nwere ọkara ndụ nke ihe dịka awa 5 ruo 9, nke pụtara na itinye uche ya na ọbara na-ebelata site na ọkara n'ime oge ahụ. Ịṅụ Rivaroxaban n'abalị nwere ike inye aka ịnọgide na-enwe ọkwa nke ọgwụ na-agbanwe agbanwe n'ime ahụ dum ehihie na abalị, nwere ike ịkwalite mmetụta ọgwụgwọ ya.

Site n'ịkwado Rivaroxaban na mgbede, ndị ọrịa nwere ike irite uru site na ọkwa ọgwụ kachasị elu na-eme n'abalị mgbe ihe ize ndụ nke ịmepụta clot nwere ike ịdị elu n'ihi ogologo oge nke enweghị ike imeghari n'oge ụra. Oge a na-adakọbara n'ụdị okirikiri okirikiri nke anụ ahụ ma nwee ike inye nchebe kachasị mma megide mmemme thrombotic.

Nkwekọrịta na oge dị oke mkpa maka idowe ọkwa ọgwụgwọ nke rivaroxaban n'ime ọbara. Ndị ọrịa kwesịrị ịgbalị ị drinkụ ọgwụ ha n'ihe dịka otu oge kwa ụbọchị iji hụ na ọnọdụ mgbochi mgbochi na-aga n'ihu. Usoro a na-eme mgbe niile na-enyere aka igbochi mgbanwe na ọkwa ọgwụ nke nwere ike ibute oge n'ihe ize ndụ nke mkpụkọ ọnụ ma ọ bụ, n'aka nke ọzọ, nnukwu ọbara ọgbụgba.

Na mgbakwunye, ụfọdụ ọnọdụ ahụike ma ọ bụ usoro nwere ike ịchọ mgbanwe na oge usoro onunu ogwu Rivaroxaban. Dịka ọmụmaatụ, enwere ike ịnye ndị ọrịa na-awa ahụ ma ọ bụ usoro mkpasu iwe ka ha were ọgwụ ikpeazụ ha Rivaroxaban Powuru n'otu oge tupu usoro ahụ iji belata ihe ize ndụ nke nsogbu ọbara ọgbụgba. Oge nkwụsịtụ tupu usoro a dabere na ihe dị iche iche, gụnyere ụdị usoro, ọrụ gbasara akụrụ onye ọrịa, na ihe ize ndụ ọbara ọgbụgba.

N'ọnọdụ ụfọdụ, ndị na-ahụ maka ahụike nwere ike ịkwado ikewa dose nke rivaroxaban kwa ụbọchị n'ime nchịkwa abụọ maka ngosipụta akọwapụtara. Usoro a nwere ike inye aka mee ka ọkwa ọgwụ kwụsie ike n'ụbọchị dum, karịsịa na ndị ọrịa nwere nnukwu ihe ize ndụ nke ihe omume thrombotic ma ọ bụ ndị nwere nkwụsị ọgwụ ọjọọ.

Ọ dị oke mkpa ịgbaso ntuziaka usoro onunu ogwu nke onye na-ahụ maka ahụike gị nyere yana ịgbaso oge enyere maka ị were Rivaroxaban. Mgbanwe ọ bụla na usoro onunu ogwu ma ọ bụ oge kwesịrị ka gị na onye na-ahụ maka ahụike gị kparịta ụka iji hụ na njikwa kacha mma nke ọnọdụ gị.

mmechi

ewere rivaroxaban ntụ ntụ n'abalị bụ a nkịtị nkwanye n'ihi ọtụtụ ihe, gụnyere nwere ike ibelata ụfọdụ mmetụta, mma, na ịnọgide na-enwe na-agbanwe agbanwe ọgwụ etoju na ahu. Nlekọta mgbede nwere ike kwekọọ n'ụda nke anụ ahụ, nwere ike ịkwalite mmetụta anticoagulant n'oge enwere nnukwu ihe egwu, dị ka enweghị ike ime abalị.

Uru dị n'iji ọgwụ eme ihe n'abalị gụnyere nrube isi na usoro ọgwụ, n'ihi na enwere ike itinye ya n'ime oge ụra. Oge a nwekwara ike inye aka belata ụfọdụ mmetụta ndị dị na ya, dị ka ike ọgwụgwụ ma ọ bụ dizziness, site n'ime ka ha mee n'oge ụra. Na mgbakwunye, maka ndị ọrịa na-enweta ahụ erughị ala afọ, iji rivaroxaban were nri mgbede dị ọkụ nwere ike inye aka belata iwe afọ.

Agbanyeghị, ọ dị mkpa ịgbaso ntuziaka ndị na-ahụ maka ahụike gị gbasara oge na nchịkwa Rivaroxaban, n'ihi na ọnọdụ onye ọ bụla na ọnọdụ ahụike nwere ike ịchọ mgbanwe. Ihe ndị dị ka ọrụ gbasara akụrụ, ọgwụ ndị na-ejikọta ọnụ, na profaịlụ ihe ize ndụ thrombotic nwere ike imetụta usoro ọgwụgwọ kachasị mma maka onye ọrịa ọ bụla.

Ndị ọrịa kwesịrị ịma maka mmekọrịta dị n'etiti rivaroxaban na ọgwụ ndị ọzọ, mgbakwunye, ma ọ bụ nri. Mkparịta ụka mgbe niile na ndị na-ahụ maka ahụike gbasara mgbanwe ọ bụla na ọnọdụ ahụike, usoro ọgwụ, ma ọ bụ usoro ndị na-abịa dị oke mkpa maka idowe ọgwụgwọ mgbochi mgbochi dị mma ma dị irè.

Dị ka ọ dị na ọgwụ mgbochi ọ bụla, ndị ọrịa na-ewere rivaroxaban kwesịrị ịmụrụ anya maka ihe ịrịba ama nke oke ọbara ọgbụgba ma ọ bụ ọnya na-adịghị ahụkebe ma kọọrọ ndị na-ahụ maka ahụike ha ngwa ngwa. Oge nleba anya mgbe niile na ịgbaso usoro nleba anya nke edebere bụ akụkụ dị mkpa nke ijikwa ọgwụgwọ rivaroxaban nke ọma.

N'ikpeazụ, mgbe nchịkwa abalị nke Rivaroxaban Powuru nwere ike inye ọtụtụ uru, a ga-eme mkpebi maka oge site na ịkpọtụrụ onye na-ahụ maka ahụike, na-eburu n'uche mkpa onye ọrịa n'otu n'otu, akụkọ ahụike, na ihe ize ndụ ụfọdụ. Site n'iso ndị otu ahụike ha na-arụkọ ọrụ, ndị ọrịa nwere ike ịkwalite uru nke ọgwụgwọ rivaroxaban ma na-ebelata ihe egwu na mmetụta ndị nwere ike.

Ọ bụrụ na ị nwekwara mmasị na ngwaahịa a ma chọọ ịmatakwu nkọwa ngwaahịa, ma ọ bụ chọọ ịmata maka ngwaahịa ndị ọzọ metụtara, biko nweere onwe gị ịkpọtụrụ. iceyqiang@gmail.com

References:

1. Nlekọta ahụike Bayer. "Rivaroxaban (Xarelto) Ozi na-edepụta." Enwetara June 20, 2024.

2. Frost, C., et al. "Pharmacokinetics nke rivaroxaban na ndị ọrịa nwere fibrillation atrial: nyochaa." Akwụkwọ akụkọ nke Thrombosis na Thrombolysis, vol. 46, mba. 2, 2018, p. 255-264 .

3. Pollack, CV, et al. "Na-ebuli ojiji nke Rivaroxaban na ndị ọrịa nwere Atrial Fibrillation." Ụlọ ọgwụ gbasara obi obi, vol. 36, mba. 2, 2018, p. 235-247 .

4. Samama, MM, et al. "Rivaroxaban maka thromboprophylaxis mgbe ịwa ahụ orthopedic: nyochaa usoro ihe omume ụlọ ọgwụ." Nyocha ndị ọkachamara banyere ọgwụgwọ obi, vol. 13, mba. 11, 2015, p. 1273-1286.

5. Turpie, AG, et al. "Rivaroxaban maka mgbochi nke venous thromboembolism mgbe hip ma ọ bụ ikpere arthroplasty." Akwụkwọ akụkọ New England nke Medicine, vol. 365, mba. 6, 2011, p. 510-519 .

6. Weitz, JI, et al. "Rivaroxaban: A ọhụrụ ọgwụ anticoagulant maka ọgwụgwọ nke venous thromboembolism na mgbochi nke ọrịa strok na atrial fibrillation." Thrombosis na Hemostasis, vol. 110, mba. 5, 2013, p. 823-834 .

7. Zhu, T., et al. "Pharmacokinetics na nchekwa nke rivaroxaban na ndị ọrịa nwere ogo dị iche iche nke ọrịa akụrụ." Nnyocha thrombosis, vol. 142, 2016, p. 87-93 .

8. Ageno, W., et al. "Ọgwụgwọ anticoagulant nke ọnụ: Usoro ọgwụgwọ Antithrombotic na Mgbochi nke Thrombosis, 9th ed: American College of Chest Physicians Evidence-based Clinical Practice Guidelines." Igbe, vol. 141, mba. 2 Suppl, 2012, p. e44S-e88S.

9. Agnelli, G., et al. "Rivaroxaban versus enoxaparin maka thromboprophylaxis mgbe ngụkọta ikpere arthroplasty." Akwụkwọ akụkọ New England nke Medicine, vol. 365, mba. 17, 2011, p. 1597-1607.

10. Eriksson, BI, et al. "Rivaroxaban megide enoxaparin maka thromboprophylaxis mgbe ọkpụkpụ arthroplasty gasịrị." Akwụkwọ akụkọ New England nke Medicine, vol. 358, mba. 26, 2008, p. 2765-2775.